SCHEMBL21303665

SCHEMBL21303665

c1ccc(COc2ccc(CNc3cnc4[nH]cnc4c3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.56
▸ MAPT P10636 3/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ ATM Q13315 1/20 0.54
▸ BCHE P06276 2/20 0.49
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ MRGPRX1 Q96LB2 1/20 0.48
▸ IP6K1 Q92551 2/20 0.47
▸ MAPK1 P28482 1/20 0.45
▸ PPARA Q07869 2/20 0.45
▸ PDGFRB P09619 1/20 0.44
▸ PDGFRA P16234 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22448314 0.89 IP6K1 (0.56) IP6K1MAPK1PDGFRBPDGFRAALDH1A1
SCHEMBL21303660 0.84 IP6K1 (0.51) MEN1KMT2AIP6K1PDGFRBPDGFRA
SCHEMBL21303664 0.83 MAPT (0.51) MAPTMEN1GAABLMKMT2A
SCHEMBL21303624 0.82 ABL1 (0.42) MAPTGAAKMT2AKDM4EALDH1A1
SCHEMBL21303604 0.82 ABL1 (0.40) MAPTGAAIP6K1KDM4EALDH1A1
SCHEMBL21303616 0.81 FFAR1 (0.51) MAPTMEN1GAABLMKMT2A
SCHEMBL21303605 0.80 ABL1 (0.42) F2MAPTKMT2ATP53IP6K1
SCHEMBL21303627 0.78 RAB9A (0.47) MAPTMEN1KMT2AIP6K1KDM4E
SCHEMBL21303661 0.77 QPCT (0.51) MAPTMEN1GAAKMT2ATP53
SCHEMBL21303622 0.76 LTA4H (0.54) MAPTMEN1GAAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11958871-B2 Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2024-04-16 — — US disclosed
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2020-12-17 — — US disclosed
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2020-12-17 — — US disclosed
EP-3589632-B1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) 2020-09-23 — — EP disclosed
EP-3589632-B1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung Ev (DE) 2020-09-23 — — EP disclosed
WO-2019162458-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2019-08-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392174-A1 NOVEL INHIBITORS OF BACTERIAL GLUTAMINYL CYCLASES FOR USE IN THE TREATMENT OF PERIODONTAL AND RELATED DISEASES GMPS, GLS, QPCT F2 4302/4885MAPT 4289/4885MEN1 4589/4885
US-11958871-B2 Inhibitors of bacterial glutaminyl cyclases for use in the treatment of periodontal and related diseases GMPS, GLS, QPCT F2 4057/4885MAPT 4117/4885MEN1 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback